Tragiannidis Athanasios, Gombakis Nikolaos, Papageorgiou Maria, Hatzipantelis Emmanuel, Papageorgiou Theodotis, Hatzistilianou Maria
2nd Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Greece
2nd Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Greece.
Int J Immunopathol Pharmacol. 2016 Dec;29(4):729-730. doi: 10.1177/0394632016670667. Epub 2016 Sep 19.
Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) is a devastating early or late complication of treatment for childhood cancer related with a significant morbidity and mortality. We retrospectively studied survivors of childhood cancer. Overall, 287 patients were recorded in the databases and we identified three (1.04%) with t-MDS. The primary cancer diagnoses were Langerhans cell histiocytosis (one patient) and acute lymphoblastic leukemia (ALL; two patients). The mean age of patients was 12.1 years. All patients had received systemic antifungal treatment for invasive pulmonary aspergillosis successfully treated with voriconazole and liposomal amphotericin B before diagnosis of t-MDS. Two patients (66%) remain alive after a median follow-up period of 3.5 years.
治疗相关的骨髓增生异常综合征（t-MDS）/急性髓系白血病（AML）是儿童癌症治疗中一种严重的早发或迟发并发症，具有较高的发病率和死亡率。我们对儿童癌症幸存者进行了回顾性研究。总体而言，数据库中记录了287例患者，我们识别出3例（1.04%）患有t-MDS。原发癌症诊断为朗格汉斯细胞组织细胞增多症（1例患者）和急性淋巴细胞白血病（ALL；2例患者）。患者的平均年龄为12.1岁。所有患者在诊断t-MDS之前均接受过全身抗真菌治疗，用于侵袭性肺曲霉病，采用伏立康唑和脂质体两性霉素B成功治疗。经过3.5年的中位随访期后，2例患者（66%）仍然存活。
